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The association between membranous nephropathy (MN)
and cancer is often mentioned in textbooks but poorly
substantiated, and the characteristics of cancer-associated
MN are unknown. To address these questions, we studied
a cohort of 240 patients with MN, among them 24 had
malignancy at the time of renal biopsy or within a year
thereafter. The incidence of cancer was significantly higher in
these patients than in the general population (standardized
incidence ratio 9.8 [5.5–16.2] for men and 12.3 [4.5–26.9] for
women). The frequency of malignancy increased with age.
At the time of diagnosis, clinical presentation did not differ
between the patients with cancer-associated MN and those
with idiopathic MN, but smoking was more frequent among
patients with cancer. Analysis of renal biopsies revealed that
the number of inflammatory cells infiltrating the glomeruli
was significantly higher in patients with cancer-associated
MN (P¼ 0.001). The best cutoff value for distinguishing
malignancy-related cases from controls was eight cells
per glomerulus. Using this threshold led to a diagnosis of
cancer-associated MN with a specificity of 75% and a
sensitivity of 92%. In patients with cancer-associated MN,
there was a strong relationship between reduction of
proteinuria and clinical remission of cancer (Po0.001). In
conclusion, our study provides epidemiologic evidence
of an excess of cancer risk in patients with MN. It also shows
that age, smoking, and the presence of glomerular leukocytic
infiltrates strongly increase the likelihood of malignancy
in MN patients.
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Membranous nephropathy (MN) is the most common cause
of adult-onset nephrotic syndrome in Caucasian patients. It
is characterized by the accumulation of immune deposits on
the epimembranous aspect of the glomerular basement
membrane in the absence of significant intraglomerular
cellular proliferation. There is convincing evidence that MN
can be associated with various disease processes, including
infections, autoimmune diseases, and drug toxicity.1
Although the association between MN and cancer is
frequently reported,1–10 it has been pointed out that the
notion of paraneoplasic MN is based only on a limited
number of old series and case reports showing a temporal
link between the course of MN and tumor activity, as
reviewed by Glassock2 and Ronco.3 For example, the
frequency of cancer in the MN population has been variously
estimated at between 5 and 22%,4–8 carcinomas being the
tumors most frequently associated with MN. Similarly, as
pointed out by Ronco3 only isolated cases of remission of
MN after treatment have been reported.3,10–18 In addition, up
to now the available data have not permitted comparison of
the incidence of cancer in the MN population with that in the
general population, nor the determination of distinguishing
clinical, laboratory, or morphological features which
should lead physicians to suspect a cancer-associated MN.
To try to resolve these issues, we have analyzed the incidence
of cancer in a cohort of 240 patients with MN, as well
as the characteristics and outcome of these cancer-associated
MNs.
RESULTS
Incidence of cancer among patients with MN
The prevalence of cancer among patients with MN was 10%.
It significantly increased with age (Po0.001), but was not
related to gender (Table 1).
Among the 21 incident cases of cancer associated with
MN, the tumor was symptomatic at the time of renal biopsy
in only 11 patients (52%). Nine presented specific tumor-
related symptoms (cough, urinary retention, y) and two
had impairment of general health status. For the remaining
10 patients (48%) the tumor was asymptomatic and only
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recognized by systematic diagnostic procedures triggered by
the diagnosis of MN.
Compared with the general population, the incidence of
cancer among patients with MN was about 10 times higher in
all age groups and in both genders (Table 2). Standardized
incidence ratio (SIR) remained highly significant in both men
and women, even if it was assumed that none of the 47
patients with no medical record or lost to follow-up
developed cancer (SIR 8.6 [95% confidence interval (CI):
4.8–14.2], and 10.7 [95% CI: 3.9–23.4], respectively). After
restricting the analysis to patients whose tumors were
symptomatic at the time of diagnosis of MN, SIR also
remains significant in men: SIR 7.1 [95% CI: 3.4–13] for men
and 4.4 [95% CI: 0.5–16] for women.
Types of cancer associated with MN
The vast majority of tumors associated with MN were
carcinomas (20 cases, 83.3%), and the most frequent
localizations were lung (eight cases) and prostate (five cases),
(Table 3). In men, the SIR was 31.9 for lung cancer (95% CI:
12.8–65.7) and 12.1 for prostate cancer (95% CI: 4–28.3). Two
tumors were of hematopoietic origin and two others were
rare malignancies: a mediastinal liposarcoma and a malignant
micronodular thymoma with capsular and perithymic
adipose tissue invasion.
Baseline characteristics of cancer-associated membranous
nephropathies
Patients with cancer-associated MN were significantly older
than controls, but the male to female sex ratio was similar
between the two groups (Table 4). Clinical and laboratory
data at the time of renal biopsy did not significantly differ
between cases and controls, with the exception of estimated
glomerular filtration rate (Table 4). However, this difference
was no longer significant after adjusting for age. The higher
percentage of hematuria in cases than in controls was border-
line significant (P¼ 0.06). Patients with cancer-associated
MN were more often heavy smokers (X20 pack-years) than
controls (Po0.01).
A thrombotic event was diagnosed during the initial
evaluation of the nephropathy in 25% of patients with
cancer-associated MN, and it was responsible for pulmonary
embolism in one case. No renal vein thrombosis was
observed, in spite of systematic search by colored-coded
duplex sonography.
Comparison of renal biopsies between patients with
cancer-associated MN and the 24 matched controls are
shown in Table 5. Patients with cancer-associated MN tended
to have more often stage I MN, but this difference was not
statistically significant. More importantly, the number of
inflammatory cells infiltrating the glomeruli was significantly
higher in the group of patients with cancer-associated MN
(P¼ 0.001), (Table 5 and Figure 1). According to the
receiver-operating characteristic curve, the best cutoff value
for distinguishing malignancy-related cases from the controls
was eight cells per glomerulus. Using this threshold led to the
diagnosis of cancer-associated MN with a specificity of 75%
and a sensitivity of 92%. The area under the curve was 0.92.
The number of inflammatory cells per glomerulus was not
correlated with age, history of smoking, stage of MN, type of
tumor, or the presence of metastases.
Course of patients with cancer-associated MN
Dialysis-free survival was not used as an end-point, as dialysis
may not have been offered to all patients with cancer. As
expected, survival with estimated glomerular filtration rate
Table 1 | Distribution of cancer cases among patients with MN by age and gender
Men Women Total
Age MN T % MN T % MN T %
18–54 88 2 2.3 47 1 2.1 135 3 2.2
55–64 21 2 9.5 11 1 9.1 32 3 9.4
X65 45 13 28.9 28 5 17.9 73 18 24.7
Total 154 17 11.0 86 7 8.1 240 24 10.0
MN, membranous nephropathy.
MN, number of patients with MN; T, number of patients with MN and cancer; %, percentage of MN patients with cancer.
Table 2 | SIR of cancer in a cohort of 240 patients with MN, as compared to the French general population
Men Women
Age O E SIR (95 %CI) O E SIR (95 %CI)
18–54 2 0.20 10.2 (1.1–36.7) 1 0.10 9.5 (0.1–52.7)
55–64 2 0.23 8.6 (1.0–31.1) 1 0.08 13.0 (0.2–72.4)
X65 11 1.10 10.0 (5.0–17.9) 4 0.30 13.2 (3.5–33.7)
Total 15 1.53 9.8 (5.5–16.2) 6 0.49 12.3 (4.5–26.9)
CI, confidence interval; MN, membranous nephropathy; O, number of incident cancers observed in the group of patients with MN; E, expected number of cancers in this
group of patients, estimated using 2000 cancer incidence rates in the French population.35 ; SIR, standardized incidence ratio.
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415 ml/min/1.73 m2 was significantly worse in patients with
cancer-associated MN than in those with idiopathic MN
(Figure 2). Sixteen patients (66.7%) with cancer-associated
MN died during follow-up, as compared to only two patients
(8.3%) with idiopathic MN (Po0.001). The death was
secondary to neoplasia in seven patients (43.8%), to
complications of nephropathy in three patients (two infec-
tions, one pulmonary embolism), to cardiovascular disease in
three patients and to various causes in the last three. The two
patients with idiopathic MN died from sepsis and vascular
Table 3 | Types of cancer and outcome of tumor and nephrotic proteinuria among 24 patients with cancer-associated MN
Remission
Localization of tumor Histology N M/F Stage
Treatment
of tumor Tumor
Nephrotic-range
proteinuria
C34 Bronchus and lung Adenocarcinoma 4 3/1 T2N1M0 S + C
T2N2M0 S+R  
T2N2M1 R  
T2N2M1 —  
Squamous cell carcinoma 4 4/0 T1N0M0 S + C
T2N1M0 S+R+Ch + C
T2N2M0 S+R + P
T2N2M0 S+R  
C61 Prostate Adenocarcinoma 5 5/0 T2NxM0 H + C
T2NxM0 H+Cs+R + P
T3NxM0 H+R  
T3NxM0 S+H+Cs  
T3NxM1 H  
C16 Stomach Adenocarcinoma 2 1/1 T1N0M0 S + 
T2N1M1 —  
C18 Colon Adenocarcinoma 1 1/0 Dukes D Ch  
C32 Larynx Squamous cell carcinoma 1 1/0 T2N2M0 R  
C37 Thymus Micronodular thymoma 1 0/1 Masoaka II S+R + C
C38 Mediastinum Liposarcoma 1 1/0 T3N0M0 S + P
C67 Bladder Transitional cell carcinoma 1 1/0 T4N1M0 S+R  
C53 Cervix uteri Squamous cell carcinoma 1 0/1 T2N0M0 R + 
C50 Breast Infiltrating duct carcinoma 1 0/1 T2N0M0 S+R+H + 
C83 Diffuse non-Hodgkin’s lymphoma Follicular B-cell lymphoma 1 0/1 Cs+Cy + C
C92 Chronic myeloid leukaemia 1 0/1 Ch  
Numbers heading the cancer localization are from the International Classification of Disease (ICD-10-CM); C, complete remission of nephrotic-range of proteinuria;
Ch, chemotherapy without steroids or alkylating agents; Cs, chemotherapy including steroids; Cy, chemotherapy including alkylating agents; H, hormonal therapy M/F, male-
to-female ratio; MN, membranous nephropathy; N, number of patients; P, partial remission of nephrotic-range proteinuria; R, radiotherapy; S, surgery.
Table 4 | Clinical and laboratory data at the time of renal biopsy for patients with cancer-associated MN and controls
Characteristics Cancer-associated MN Controls Age-adjusted P-value
N 24 129 —
Men 71% 71% NS
Age (years) 73 (65–78) 52 (39–69) o0.001
Age X65 years 75% 33% o0.001
Proteinuria (g/day or g/g creatinine) 6.8 (5.0–10.3) 6.0 (3.6–8.1) NS
Proteinuria 43 g/day or g/g creatinine 96% 84% NS
Proteinuria 410 g/day or g/g creatinine 25% 17% NS
Serum albumin (g/l) 20 (17–25) 23 (17–28) NS
Hematuria 54% 34% NS
Serum creatinine (mmol/l) 109 (84–156) 88 (73–107) NS
eGFR (mL/min/1.73 m2) 59 (40–83) 78 (61–95) NS
eGFR o60 ml/min/1.73 m2 54% 25% NS
eGFR o30 ml/min/1.73 m2 17% 7% NS
Hypertension 71% 60% NS
SBP (mmHg) 140 (125–158) 140 (130–160) NS
DBP (mmHg) 80 (70–88) 80 (72–90) NS
Ever smoking 68% 56% NS
Heavy smoking (X20 pack-years) 68% 29% o0.01
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MN, membranous nephropathy; NS, nonsignificant; SBP, systolic blood pressure.
Results are expressed as median (interquartile range) or as percentage.
NS: P-value40.05.
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stroke. The median survival time after the diagnosis of MN
was only 13 months (interquartile range 11–36 months) in
patients with cancer. Ten patients (41.7%) with cancer-
associated MN developed chronic kidney disease stage 5
versus 8 (33.3%) with idiopathic MN (NS).
Twenty-three patients with cancer-associated MN and 20
controls had nephrotic-range proteinuria at the time of
diagnosis. During follow-up, complete remission was ob-
served in six cases and six controls and partial remission in
three cases and seven controls. In the malignancy-related
group, all remissions occurred in patients whose tumor was
also in remission, whereas tumor was considered as being in
remission, in only three of the 14 patients with persistent
nephrotic-range proteinuria. Thus, there is a significant
relationship between the reduction in proteinuria and
remission of cancer (Po0.001). The treatments received by
the 24 patients with cancer-associated MN are summarized in
Table 3. Only two of the nine patients with combined
remission of both nephrotic syndrome and cancer were
treated with chemotherapy including corticosteroids (both
patients) and cyclophosphamide (one patient). The other
patients were treated by surgery (6/9), radiotherapy (4/9)
and/or hormonal therapy (1/9), or chemotherapy not using
steroids or alkylating agents (1/9).
DISCUSSION
As with earlier studies, we observed a high frequency of
cancer in patients with MN. However, ours is the first to
show a significant increase in cancer among patients with
MN in comparison with the general population. It is also the
first to suggest that there is a histological marker predictive of
cancer, and to indicate a clear link between decrease in
proteinuria and tumor remission. These findings are
noteworthy because they are based on a large and nonselected
cohort of patients with histologically proven MN.
Our study shows that 10% of patients diagnosed with MN
had cancer. These data are in agreement with older series in
which the frequency of cancer in MN population has been
variously estimated from 5 to 22%.4–8 However, none of these
series has compared the incidence of cancer in this group
with that in the general population. In our study, this was
about 10-fold higher in patients with MN than in the general
population. Even when restricting the analysis to the patients
whose tumors were symptomatic at the time of diagnosis of
MN, the worst case assumption in a country with widespread
cancer screening, the incidence remained high. Thus, the
excess of malignancy in patients with MN cannot be explai-
ned by a detection bias. Although the observed-to-expected
Table 5 | Comparison of renal biopsies between patients with cancer-associated MN and controls
Histological parameter Cancer-associated MN Controls P-value
Stage I MN 33.3% 12.5% NS
Stage II MN 41.7% 58.3% NS
Stage III MN 25% 29.2% NS
Sclerotic glomeruli425% 16.7% 25% NS
FSGS lesionsa 12.5% 29.2% NS
Glomerular congestion 20.8% 33.3% NS
Number of inflammatory cells/glomerulusb 12.8 (10.2–15.5) 5 (3.5–7) 0.001
48 Inflammatoty cells/glomerulus 91.7% 25% o0.001
Interstitial fibrosis410% 58.3% 45.8% NS
Interstitial fibrosis420% 29.2% 45.8% NS
Arteriosclerosis 70.8% 83.3% NS
Glomerular microthrombi 8.3% 0 NS
Focal cortical atrophy 4.2% 0 NS
FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy; NS, nonsignificant.
Results are expressed as median (interquartile range) or as percentage.
aSuperimposed lesions of FSGS.
bIncludes polymorphonuclear and mononuclear leukocytes.
a b
Figure 1 | Representative example of a glomerulus from a patient
with idiopathic MN (a) and from a patient with cancer-associated
MN (b). (a) The glomerulus contains only one mononuclear cell (-).
(b) Numerous inflammatory cells are present within the glomerulus
(-). Masson’s trichrome stain, original magnification  100.
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Figure 2 | Kaplan–Meier plot of survival with glomerular filtration
rateX15 ml/min/1.73 m2 in patients with cancer-associated MN
and controls. Solid line: patients with cancer-associated MN. Dotted
line: patients with idiopathic MN. Dot: censored patient.
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ratios were similar in all age groups, cancer was diagnosed in
one out of four patients with MN over age 65 and only in one
out of 50 patients under age 55 (Table 2). In contrast, gender
was not a determinant of association with cancer among MN
patients. To present, the sole population study has been that
of Birkeland and Storm, which found an excess of cancers in
patients with glomerulopathies, including MN in men.9 In
that study the SIR was 1.79 for men (95% CI: 0.95–3.05) and
1.97 for women (95% CI: 0.79–4.07). The differences in SIR
between our study and the one of Birkeland and Storm may
be due to methodological differences. In the latter study,
classification of MN as being cancer-associated was solely
based on a record linkage between the Danish Kidney
Biopsy and Cancer Registries, without systematic analysis
of individual medical records. This method may have
lacked sensitivity in detecting cancer cases, and led to an
underestimation of SIR.
Our study establishes a clear correlation between remis-
sion of cancer and remission of nephrotic syndrome in
patients with cancer-associated MN. Up to now, only isolated
cases of remission of MN after treatment of the neoplasm
have been reported, with a total of less than 20 cases related
to tumors in the last 10 years.3,10–18 In our study, complete
remission of nephrotic syndrome occurred in six out of
12 patients whose tumor was in remission but in none of
12 patients whose tumor was not in remission. Importantly,
only one patient with complete remission of nephrotic
syndrome received a chemotherapy including steroids plus
alkylating agents. The temporal link between complete
remission of nephrotic syndrome and tumor remission
strongly argues in favor of a causal relationship between
the two diseases.
As suggested by previous case reports, carcinomas were by
far the tumors most often associated with MN. In our cohort,
the cancers most frequently associated with MN were lung
(eight) and prostate (five), whereas association between
prostate cancer and MN has rarely been reported.19 It is likely
that prostate cancer has been under-recognized in older series
owing to the lack of serologic marker, whereas measurement
of prostate-specific antigen is now systematic in aging men.
Based on our study showing an increased incidence of
prostatic and lung cancer among MN patients, we suggest
systematic investigation for possible prostatic or pulmonary
tumor among patients over 65 years of age, as the first
priority, before investigation of other possible primary sites.
Interestingly, none of the malignancies associated with MN
were skin cancer, despite the fact that this type of cancer is
extremely common in elderly people. This is consistent with
the fact first that skin cancers associated with MN have rarely
been reported in the literature, and second that only
melanoma, Kaposi’s sarcoma or cutaneous T-cell lymphomas
have been reported in association with MN.20–22
In our study, the clinical presentation of cancer-associated
MN could not be distinguished from that of idiopathic MN,
with one noticeable exception; heavy smoking (X20 pack-
years) was more frequent among patients with cancer. In
previous studies of biopsies in malignancy-related MN,
efforts have focused on detection of tumor antigens, rather
than on comparative studies of potential differences separat-
ing such cases from idiopathic MN. In the present study,
systematic analysis revealed that on average, the number of
inflammatory cells infiltrating the glomeruli was more than
twofold higher in patients with cancer. Using a receiver-
operating characteristic curve, we could determine a cutoff
value of eight cells per glomerulus. The area under the curves
indicates that based on this marker, 92% of the patients
would be correctly classified as having or not having cancer.
Thus, the determination of the number of leukocytes
infiltrating the glomerular capillaries appears to be a useful
exercise, and if they are increased, an additional incitement to
pursue the investigation of malignancy in these MN patients.
However, although the basic observation of an increase in the
number of glomerular leukocytes is clearly valid given the
sample sizes (272 glomeruli in cancer-associated MN and 311
glomeruli, in idiopathic MN), we recognize that the cutoff
value that we have defined needs to be validated in an
independent cohort.
It is not clear why patients with cancer-associated MN
have more inflammatory cells infiltrating the glomeruli. One
possibility would be that the deposition of immune complex
containing tumor-associated antigens induces the release of
proinflammatory molecules. However, one should keep in
mind that the number of infiltrating cells is limited, much
smaller than what is seen in renal biopsies from patients with
mixed cryoglobluliemia or post-infectious glomerulonephri-
tis. Numerous studies have attempted to establish patho-
physiologic links between the tumor and the renal lesion.
Different tumoral antigens23–25 or their specific anti-
bodies26,27 have been identified in the kidneys of these
patients, but without definite proof of their pathogenic nature.
Interestingly, Ohtani et al.28 found that the staining observed
with anti-immunoglobulin (Ig)G1 and anti-IgG2 antibodies
was stronger in cancer-associated MN than in idiopathic MN.
These results suggest that the immune processes involved in
the pathogenesis of cancer-associated MN are different from
those of idiopathic MN, with a predominance of Th1-type
responses in cancer-associated MN.28
Although this study is the largest cohort of cancer-
associated MN to date, the number of cases remains small
and we may have lacked power in some comparisons with
idiopathic MN. A second limitation is that this is strictly an
observational study, and it seems likely that more systematic
search for cancer might have revealed that the incidence of
cancer among MN patients was still underestimated.
However, as we have shown, a wide variety of cancers were
associated with MN, such that, with the exception of lung
and prostate primaries, a systematic strategy for investigation
of MN patients cannot be clearly defined.
This study has important clinical implications. First of all,
it confirms and gives dimensions to the long-held belief that
there is an increased incidence of cancer, principally
carcinomas, among MN patients, particularly in those over
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age 65. Secondly, it offers a morphologic screening tool,
in the form of glomerular leukocytes on renal biopsy.
Their presence in numbers is indicative of a particularly high
risk of cancer in these patients. This is particularly useful,
given that in more than 50% of patients the tumor was
asymptomatic at the time of renal biopsy. The study also
points to two particularly frequent primary sites, lung and
prostate, which must be systematically sought in patients
over age 65. Beyond these two possibilities, the clinical
workup should be guided by the clinical situation and risk
factors (e.g. smoking as a risk factor in lung, upper
respiratory, and bladder primaries).
In conclusion, our cohort strongly supports the existence
of an association between cancer and MN. It also points out
two risk factors, age and smoking, and suggests a new
morphological risk marker. Further research is needed to
define the best cancer screening strategy in MN patients.
MATERIALS AND METHODS
Subjects
This study has been conducted in 11 Departments of Nephrology
located in the Paris region (see Appendix for a list of participating
centers), after being approved by the ethics committee of Paris-Saint
Louis. Patients were identified on the basis of the renal biopsy files of
the affiliated Department of Pathology. All adult patients (418
years old) in whom a MN was first diagnosed between January 1994
and June 2001 were considered for inclusion. Medical records were
available for 240 (84%) out of 287 patients on file; data system-
atically included antinuclear antibodies, serology for hepatitis B and
C, current treatment and whether cancer was diagnosed before, at
the time of, or following the diagnosis of MN. All these records were
reviewed by two nephrologists (X Belenfant and O Kourilsky) and
one pathologist (Y Allory), in order to confirm the diagnosis of MN
and determine its etiology. MN was considered as being idiopathic
in 141 cases, and associated with autoimmune disease, infection or
drug toxicity in 75 cases, and with cancer in 24 patients. In all 24
cases, malignancy was histologically proven. The diagnosis of cancer
and MN was performed within a year in 21 cases, and these patients
will be further referred to as incident cancer cases. In the three
remaining patients, cancer was known more than 1 year before MN
(13, 16, and 60 months, respectively), but was still active at the time
of renal biopsy. These patients were therefore considered in the
group of cancer-associated MN.
Controls included all patients with idiopathic MN. Of these, 24
patients were randomly selected for studying renal biopsies and
long-term outcome and were considered as matched controls.
Randomization was performed after stratifying by age (o55, 55–64,
and X65 years) and gender in order to obtain the same number of
cases and controls in each stratum.
Clinical and biological data
Baseline data at the time of renal biopsy were obtained from medical
records for all cases and 129 (92%) of the controls with idiopathic
MN, including: age, sex, ethnicity, comorbidities, past medical
history, past and current medications, blood pressure, serum
creatinine, serum albumin, hemoglobin, proteinuria (expressed in
g/day or as a protein to creatinine ratio), urine sediment, and
smoking (ever versus never, number of pack-years). In cases and
matched controls, these data were also gathered up to June 2004.
Hypertension was defined by a systolic blood pressure
4140 mmHg or a diastolic blood pressure 490 mmHg or the need
for anti-hypertensive medication. Nephrotic range proteinuria was
defined by proteinuria 43 g/day or a protein to creatinine ratio
43 g/g. Hematuria was defined by the presence of more than 10 red
blood cell per mm3. Glomerular filtration rate was estimated using
the abbreviated Modification of Diet in Renal Disease Study
equation,29 and chronic kidney disease was classified according to
Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.30
Complete remission of nephrotic range proteinuria was defined by
proteinuria o0.3 g/day or protein to creatinine ratio o0.3 g/g.
Partial remission was defined by proteinuria o3 g/day and a 50%
reduction in proteinuria.
For patients with cancer, the associated tumor was classified
according to the International Classification of Diseases ((ICD)-10-
CM of World Health Organization (WHO)),31 and staged according
to the international tumor node metastasis classification.32
Analysis of renal biopsies
Renal biopsies from all patients with cancer-associated MN and
from the matched controls were reviewed by two renal pathologists
(DN and GSH), blinded to the clinical and laboratory data. They all
contained at least nine glomeruli. They were stained by standard
methods for light microscopy analyses. Immunofluorescence studies
were performed using polyclonal antibodies to IgA, IgG, IgM, fibrin,
albumin, C3, C4, and C1q (Behringwerke, Marburg, Germany) and
anti-kappa and anti-lambda light chains monoclonal antibodies
(Dako, Glostrup, Denmark).
MN were classified into four stages according to the criteria of
Barie´ty and Ehreinreich: stage I, normal basement membrane on
light microscopy associated with evidence of IgG deposits on
immunohistochemical studies; stage II, presence of basement-
membrane spikes; stage III, incorporation of some deposits into
the basement membrane; and stage IV, markedly thickened
basement membrane.33
A variety of basic lesions were systematically evaluated on each
renal biopsy. Sclerotic glomeruli with evidence of focal segmental
glomerulosclerosis were counted and expressed as percentages. The
degree of interstitial fibrosis was estimated as a percentage of the
parenchyma. Other lesions, including arterial, arteriolar, tubular
lesions, and inflammatory infiltrates, were evaluated on a semi-
quantitative scale of 0–3. The presence of intraglomerular thrombi
was also evaluated.
The initial semiquantitative analyses showed more glomerular
inflammatory infiltrates in cancer-associated MN than in idiopathic
MN. Therefore, for each biopsy, all leukocytes, both polymorpho-
nuclear and mononuclear, found within the capillary lumens of all
glomeruli, were systematically counted. For each glomerulus, we
considered the section with the largest diameter. The mean number
of inflammatory cells per glomerulus was then calculated for each
biopsy. A total of 583 glomeruli were analyzed (272 in the group of
patients with cancer and 311 in the control group). The
interobserver variability of the count was 10.8%.
Statistical analyses
SIR of cancer in the cohort of patients with MN as compared to the
general population was estimated using 2000 cancer incidence rates
in France as the reference.34 Observed cases were the 21 incident
cancer cases. Expected cases were calculated for each 5 years stratum
of the cohort and by gender. National estimates of overall and site-
specific cancer incidence by gender and 5 year age group were
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provided by the National Institute of Public Health Surveillance
(InVS) cancer registry network35 which methods are described in.34
SIR was estimated by age group and by gender as well as for the
most frequent types of cancers (lung and prostate). To assess the
robustness of these estimates, we performed two subsidiary analyses.
First, in order to limit the potential overestimation of SIR that may
have resulted from the screening for malignancies in asymptomatic
patients with MN, we performed an analysis including only patients
whose tumor was symptomatic at the time of diagnosis of MN.
Second, to assess the magnitude of the error which may have
resulted from not including the 47 patients whom medical record
could not be traced, SIR were estimated assuming that none of them
had developed cancer. For these subjects, we used date of birth and
gender available from the renal biopsy files.
Patient’s baseline clinical and biological data were compared
between cases and the entire control group using the logistic
regression adjusting for age. Renal biopsy and follow-up data were
compared between cases and the 24 matched controls. To study the
usefulness of the number of inflammatory cells per glomerulus as a
specific marker of cancer in patients with MN, a receiver-operating
characteristic curve was plotted to estimate the best cutoff in terms
of making the highest sensitivityþ specificity/2. We also determined
the area under the curve to evaluate the ability of this marker to
discriminate patients who may or may not have cancer.
Kaplan–Meier survival estimates were calculated for the death or
chronic kidney disease stage 5 (dialysis or estimated glomerular
filtration rate o15 ml/min/1.73 m2) whichever came first. Survival
curves were compared between cancer-associated MN cases and
controls using the log-rank test.
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